Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13952029 | 1.00 | OPRM1 (0.37) | OPRM1CCR5LMNATSHRPOLB | |
| SCHEMBL13930681 | 0.90 | OPRM1 (0.37) | OPRM1CCR5 | |
| SCHEMBL13930682 | 0.85 | OPRM1 (0.37) | OPRM1CCR5 | |
| SCHEMBL13930686 | 0.85 | OPRM1 (0.38) | OPRM1 | |
| SCHEMBL13929287 | 0.84 | MEN1 (0.41) | OPRM1TSHRNPY2RSMN1; SMN2 | |
| SCHEMBL13930683 | 0.84 | KCNJ6 (0.41) | OPRM1CCR5TSHRSMN1; SMN2 | |
| SCHEMBL13930675 | 0.84 | OPRM1 (0.37) | OPRM1CCR5 | |
| SCHEMBL13930676 | 0.83 | OPRM1 (0.40) | OPRM1POLB | |
| SCHEMBL13930691 | 0.82 | OPRM1 (0.41) | OPRM1 | |
| SCHEMBL13930679 | 0.82 | OPRM1 (0.37) | OPRM1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | OPRM1 202/4885CCR5 286/4885LMNA 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.